Live Chat on The Biotech Forum has been dominated by discussion of covered call opportunities in recent quarters. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just initiate your two-week no obligation free trial into The Biotech Forum by clicking HERE .I last looked at a small cap called Vericel Corporation (NASDAQ: VCEL ) in late 2024. I slapped a 'Sell' rating on the stock at the time as its valuation was getting extreme despite its growth. The sharesBr ...

Group 1 - The article highlights CorMedix Inc. (NASDAQ: CRMD) as a focus for investment, particularly due to its flagship product, an antimicrobial catheter, which is entering full commercialization [2] - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live discussions on trade ideas and weekly market commentary [2] - The article emphasizes the importance of real-time trading ideas and discussions among seasoned biotech investors within the forum [1] Group 2 - The analyst has a beneficial long position in CRMD shares, indicating confidence in the company's potential [3] - The article does not provide specific financial metrics or performance data for CorMedix, focusing instead on the investment community's interest and engagement [2][3]

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, I am putting Travere Therapeutics, Inc. (NASDAQ: TVTX ) in the spotlight for the first time. The stock has pulled back some even as the company posted impressive sales growt ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, I am putting Avadel Pharmaceuticals (NASDAQ: AVDL ) back in the spotlight. We last looked at this promising biopharma concern just over three months ago. However, there has ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several quarters. To see what I am targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Mid-cap oncology concern Exelixis, Inc. (NASDAQ: EXEL ) posted more than solid first-quarter results after the bell on Tuesday. Management also raised forward guidance significantly. The company is going through somewh ...

Group 1 - The article discusses the recent focus on covered call opportunities within the biotech sector, particularly in the context of ACADIA Pharmaceuticals Inc. [1] - ACADIA Pharmaceuticals has been revisited due to a significant influx of new data points since the last analysis in March, indicating ongoing developments in the company [2] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live discussions and weekly updates on market commentary and portfolio performance [2] Group 2 - The author has a beneficial long position in ACADIA Pharmaceuticals, indicating a personal investment interest in the company's stock [3] - The article emphasizes that past performance does not guarantee future results, highlighting the inherent uncertainties in investment decisions [4]

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are putting Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL ) in the spotlight. This mid-cap MASH pioneer posted its first quarter results to start this month. In March of l ...

Group 1 - The article highlights the increasing interest in covered call opportunities within the biotech sector, particularly in recent quarters [1] - Talkspace, Inc. (NASDAQ: TALK) is being spotlighted for the first time in 2025, following a previous article in June of the prior year, indicating a positive incremental movement in the stock [2] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Talkspace, Inc. or other companies mentioned [3][4]